Dextera Surgical Signs Agreement with B. Braun Surgical S.A. for MicroCutter Distribution in Spain
October 17 2016 - 8:00AM
Dextera Surgical Inc. (Nasdaq:DXTR), manufacturer of the
smallest-profile and most maneuverable articulating surgical
stapler platform on the market for minimally invasive surgery,
today announced the company has entered into a marketing and
distribution agreement with B. Braun Surgical S.A. to bring
Dextera’s MicroCutter 5/80 surgical stapler to surgeons in Spain.
B. Braun Surgical S.A. is the distribution arm of the B. Braun
Aesculap Group headquartered in Tuttlingen Germany, a global leader
in developing, manufacturing and marketing innovative medical
products and services in the healthcare industry. B. Braun
Surgical S.A. holds as well the Center of Excellence (CoE) within
the Group for Closure Technologies, leading the global
responsibility for business operations in surgical sutures,
surgical meshes and stapling devices.
Under the terms of the agreement, B. Braun Surgical S.A. will
have exclusive rights to distribute the MicroCutter in Spain
through B. Braun Surgical S.A.’s laparoscopic unit. B. Braun
Surgical S.A. has an extensive network of direct and indirect sales
representatives in Spain who focus on surgeons performing minimally
invasive surgical procedures.
The MicroCutter 5/80, with its unique design and ability to
enable minimally invasive surgery, fills an important gap that
complements B. Braun’s comprehensive portfolio of surgical devices,
which includes the EinsteinVision® 3D camera system, the Caiman®
Advanced Bipolar Seal and Cut Technology and other flagship
laparoscopic instruments.
“This agreement with B. Braun Surgical S.A. in Spain is an
important and strategic first step in the expansion of our
worldwide presence with the MicroCutter,” said Julian Nikolchev,
president and CEO of Dextera Surgical. “B. Braun Surgical S.A.
brings a wealth of experience in laparoscopic and thoracoscopic
surgical instruments to leading surgeons in Spain, which makes
the company a perfect partner to continue to advance
minimally invasive surgery in Europe and around the world.”
MicroCutter Indication Information
The MicroCutter 5/80 Stapler is manufactured and cleared for use
in the United States for transection and resection in multiple open
or minimally invasive urologic, thoracic and pediatric surgical
procedures, as well as application for transection, resection
and/or creation of anastomoses in the small and large intestine,
and the transection of the appendix. The MicroCutter 30 White
Reload has application in vascular tissue.
About Dextera Surgical
Dextera Surgical designs and manufactures proprietary stapling
devices for minimally invasive surgical procedures. In the U.S.,
surgical staplers are routinely used in more than one million
minimally invasive laparoscopic, video-assisted or robotic-assisted
surgical procedures annually.
The company's signature proprietary technology, the MicroCutter
5/80 Stapler, is the world's first and only five-millimeter
surgical stapler that articulates to 80 degrees in each direction.
As the smallest-profile articulating stapler available today, the
MicroCutter 5/80 Stapler may reduce the amount of dissection and
tissue handling required to position the stapler in confined
spaces, enabling access to difficult-to-reach anatomy. The
cartridge-based device's small size and wide articulation range are
designed to enhance the surgeon's access and visualization at the
surgical site and to mitigate limitations on the advancement of
minimally invasive surgical approaches created by larger stapling
devices.
Dextera Surgical also markets the only automated anastomosis
devices for coronary artery bypass graft (CABG) surgery on the
market today: the C-Port® Distal Anastomosis Systems and PAS-Port®
Proximal Anastomosis System. These products, sold by Dextera
Surgical under the Cardica brand name, have demonstrated long-term
reliable clinical performance for more than a decade.
Forward-Looking Statements The statements in
this press release regarding the belief that the MicroCutter 5/80
will facilitate and enhance minimally invasive surgeries for
thought leaders across Spain is a "forward-looking statement."
There are a number of important factors that could cause Dextera
Surgical’s results to differ materially from those indicated by
this forward-looking statement, including: that Dextera Surgical
may not be successful in its efforts to make the improvements
necessary to its enhanced MicroCutter device due to unanticipated
technical or other difficulties; risks inherent with respect to
regulatory matters; as well as other risks detailed from time to
time in Dextera Surgical’s reports filed with the U.S. Securities
and Exchange Commission, including its Annual Report on Form 10-K
for the year ended June 30, 2016, Quarterly Report on Form
10-Q for the quarter ended March 31, 2016, under the caption
“Risk Factors.” Dextera Surgical expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to
read Dextera Surgical’s reports filed with the U.S. Securities and
Exchange Commission, available at www.sec.gov.
Contact:
Investors:
Bob Newell
Vice President, Finance and Chief Financial Officer
+1 (650) 331-7133
investors@dexterasurgical.com
Media:
Jessica Volchok
+1 (310) 849-7985
jessica@nicoleosmer.com